These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 26873788)

  • 41. Diverse injury responses of human oligodendrocyte to mediators implicated in multiple sclerosis.
    Pernin F; Luo JXX; Cui QL; Blain M; Fernandes MGF; Yaqubi M; Srour M; Hall J; Dudley R; Jamann H; Larochelle C; Zandee SEJ; Prat A; Stratton JA; Kennedy TE; Antel JP
    Brain; 2022 Dec; 145(12):4320-4333. PubMed ID: 35202462
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Endoplasmic reticulum stress response as a potential therapeutic target in multiple sclerosis.
    Getts MT; Getts DR; Kohm AP; Miller SD
    Therapy; 2008 Sep; 5(5):631-640. PubMed ID: 20357912
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiple sclerosis in 2020: un bon cru.
    Maillart E; Lubetzki C
    Lancet Neurol; 2021 Jan; 20(1):12-13. PubMed ID: 33340473
    [No Abstract]   [Full Text] [Related]  

  • 44. Primed and ready.
    Lewis S
    Nat Rev Neurosci; 2022 Apr; 23(4):189. PubMed ID: 35194224
    [No Abstract]   [Full Text] [Related]  

  • 45. Correction to: Selective Immunomodulatory and Neuroprotective Effects of a NOD2 Receptor Agonist on Mouse Models of Multiple Sclerosis.
    Fani Maleki A; Cisbani G; Laflamme N; Prefontaine P; Plante MM; Baillargeon J; Rangachari M; Gosselin J; Rivest S
    Neurotherapeutics; 2021 Apr; 18(2):1426. PubMed ID: 33907979
    [No Abstract]   [Full Text] [Related]  

  • 46. Aging and multiple sclerosis.
    Sanai SA; Saini V; Benedict RH; Zivadinov R; Teter BE; Ramanathan M; Weinstock-Guttman B
    Mult Scler; 2016 May; 22(6):717-25. PubMed ID: 26895718
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis.
    Bodini B; Veronese M; García-Lorenzo D; Battaglini M; Poirion E; Chardain A; Freeman L; Louapre C; Tchikviladze M; Papeix C; Dollé F; Zalc B; Lubetzki C; Bottlaender M; Turkheimer F; Stankoff B
    Ann Neurol; 2016 May; 79(5):726-738. PubMed ID: 26891452
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The challenge of comorbidity in clinical trials for multiple sclerosis.
    Marrie RA; Miller A; Sormani MP; Thompson A; Waubant E; Trojano M; O'Connor P; Reingold S; Cohen JA;
    Neurology; 2016 Apr; 86(15):1437-1445. PubMed ID: 26888986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Exercise Training on Fitness in Multiple Sclerosis: A Meta-Analysis.
    Platta ME; Ensari I; Motl RW; Pilutti LA
    Arch Phys Med Rehabil; 2016 Sep; 97(9):1564-1572. PubMed ID: 26896750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spring cleaning: time to rethink imaging research lines in MS?
    Absinta M; Reich DS; Filippi M
    J Neurol; 2016 Oct; 263(10):1893-902. PubMed ID: 26886204
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is Modulation of Oxidative Stress an Answer? The State of the Art of Redox Therapeutic Actions in Neurodegenerative Diseases.
    Chiurchiù V; Orlacchio A; Maccarrone M
    Oxid Med Cell Longev; 2016; 2016():7909380. PubMed ID: 26881039
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reporting treatment outcomes in observational data: A fine balance.
    Kalincik T; Sormani MP
    Mult Scler; 2017 Jan; 23(1):21-22. PubMed ID: 26883944
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.
    Zivadinov R; Uher T; Hagemeier J; Vaneckova M; Ramasamy DP; Tyblova M; Bergsland N; Seidl Z; Dwyer MG; Krasensky J; Havrdova E; Horakova D
    Mult Scler; 2016 Nov; 22(13):1709-1718. PubMed ID: 26883943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.
    Roy S; Benedict RH; Drake AS; Weinstock-Guttman B
    CNS Drugs; 2016 Mar; 30(3):209-25. PubMed ID: 26884145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm.
    Hirahara K; Nakayama T
    Int Immunol; 2016 Apr; 28(4):163-71. PubMed ID: 26874355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis.
    Bakshi R; Yeste A; Patel B; Tauhid S; Tummala S; Rahbari R; Chu R; Regev K; Kivisäkk P; Weiner HL; Quintana FJ
    Neurol Neuroimmunol Neuroinflamm; 2016 Apr; 3(2):e200. PubMed ID: 26894204
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring.
    Lapierre Y; O'Connor P; Devonshire V; Freedman MS; Kremenchutzky M; Yeung M; Schecter R
    Can J Neurol Sci; 2016 Mar; 43(2):278-83. PubMed ID: 26890887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple sclerosis prevalence in the United States commercially insured population.
    Dilokthornsakul P; Valuck RJ; Nair KV; Corboy JR; Allen RR; Campbell JD
    Neurology; 2016 Mar; 86(11):1014-21. PubMed ID: 26888980
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain.
    Haider L; Zrzavy T; Hametner S; Höftberger R; Bagnato F; Grabner G; Trattnig S; Pfeifenbring S; Brück W; Lassmann H
    Brain; 2016 Mar; 139(Pt 3):807-15. PubMed ID: 26912645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.